---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-101644"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2022-09-20T23:59:59+00:00"
generated_at: "2026-06-23T08:35:43.676108+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics appoints Matthias Alder as CEO; Eric Richman resigns effective Sept 20, 2022

## Summary
- Eric Richman resigned as CEO effective Sept 20, 2022; will remain on board through 2023 annual meeting and serve as senior advisor.
- Matthias Alder, formerly COO, appointed President and CEO and to a Board seat; receives $500k base salary, 50% target bonus, option for 60,900 shares, and 10,200 RSUs.
- Richman entitled to $27,200/month consulting fee for 12 months, plus 329,400 option and 54,900 RSUs vesting on first anniversary.
- Board adopted new non-employee director compensation policy: annual cash retainers ($40k board, $7.5k audit, etc.) plus initial option of 21,000 shares and annual award of 10,500 shares.
- One-time off-cycle annual option of 10,500 shares granted to each non-employee director on Sept 20, 2022, vesting before next annual meeting.

## SEC filing metadata
- accession: 0001104659-22-101644
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2022-09-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/tm2226134d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-101644
- JSON: https://secwatch.observer/filing/0001104659-22-101644.json
- Plain text: https://secwatch.observer/filing/0001104659-22-101644.txt

## Key facts
- Executive change
  Eric Richman resigned as Chief Executive Officer at Gain Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Eric Richman informed the Board of Directors (the “Board”) of his intent to resign as Chief Executive Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm
- Executive change
  Matthias Alder was appointed as Director at Gain Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm
- Executive change
  Matthias Alder was appointed as President and Chief Executive Officer at Gain Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Matthias Alder, the Company’s former Chief Operating Officer, has been appointed by the Board to serve as the Company’s President and Chief Executive Officer and as a member of the Board, in each case effective September 20, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.